Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study.
Sara SchrammMartha JokischKarl-Heinz JöckelArne HerringKathy KeyvaniPublished in: Alzheimer's research & therapy (2021)
This is the first population-based study to demonstrate the potential clinical utility of blood KLK8 as a biomarker for incipient AD.